(9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results